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Background   
Overexpression of microRNA-31 (miR-31) is implicated in the pathogenesis of esophageal  
squamous cell carcinoma (ESCC), a deadly disease associated with dietary zinc-deficiency. Using  
a rat model that recapitulates features of human ESCC, the mechanism whereby Zn regulates 
miR-31 expression to promote ESCC is examined. 
 
 
    
Methods  
To inhibit in vivo esophageal miR-31 overexpression in Zn-deficient rats (n = 12-20 per group),  
locked-nucleic-acid modified anti-miR-31 oligonucleotides were administered over 5- 
weeks. miR-31 expression was determined by northern blotting, qPCR, and in situ hybridization.  
Physiological miR-31 targets were identified by microarray analysis and  
verified by luciferase reporter assay. Cellular proliferation, apoptosis, and expression of  
inflammation genes were determined by immunoblotting, caspase assays, and  
immunohistochemistry. The miR-31 promoter in Zn-deficient esophagus was identified by ChIP- 
seq using an antibody for histone mark H3K4me3. Data were analyzed with t-test and ANOVA.  All  
statistical tests were two-sided.  
           
Results   
In vivo, anti-miR-31 reduced miR-31 overexpression (P =.002) and suppressed the esophageal 
preneoplasia in Zn-deficient rats. At the same time, the miR-31 target Stk40 was derepressed, 
thereby inhibiting the STK40-NF-kB controlled inflammatory pathway, with resultant decreased 
cellular proliferation and activated apoptosis (caspase 3/7 activities, fold change = 10.7, P = .005).. 
 3 
This same connection between miR-31 overexpression and STK40/NF-kB expression was also 
documented in human ESCC cell lines. In Zn-deficient esophagus, the miR-31 promoter region 
and NF-kB binding site were activated. Zn-replenishment restored the regulation of this genomic 
region and a normal esophageal phenotype.  
Conclusions  
The data define the in vivo signaling pathway underlying interaction of Zn-deficiency and miR- 
31 overexpression in esophageal neoplasia and provide a mechanistic rationale for  
miR-31 as a therapeutic target for ESCC.   
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Introduction 
 
Esophageal squamous cell carcinoma (ESCC) is a major cause of cancer death worldwide (1). 
Due to lack of early symptoms, ESCC is typically diagnosed at an advanced stage, and only 10% 
of patients survive 5-years. Thus, clarification of the mechanisms underlying the pathogenesis of 
ESCC and development of new prevention and therapeutic strategies are urgently needed.  
 MicroRNAs  (miRNAs) are short, non-coding RNAs that regulate gene expression by means of 
translational inhibition and mRNA degradation (2). Each miRNA has the ability to inhibit multiple 
target genes or entire signaling pathways, regulating a range of biological processes, including cell 
proliferation, differentiation, and apoptosis. MiRNA expression levels are altered in all human 
cancers studied (3). MiRNAs can act as oncogenes or tumor suppressors (4, 5) and have emerged 
as therapeutic targets for cancer (6). The challenge is to identify their protein targets and 
determine how these protein targets contribute to tumor initiation and progression.  
 Risk factors for ESCC include alcohol and tobacco use and known nutritional factors such as 
Zn-deficiency (7). Our well-characterized Zn-deficient (ZD) rat esophageal cancer model 
reproduces the ZD (7) and inflammation feature of human ESCC (8) and is exquisitely sensitive to 
esophageal tumorigenesis by environmental carcinogens (9, 10). We have previously shown that 
rats on a ZD diet for 5 weeks develop hyperplastic esophagi with a distinct gene signature that 
includes upregulation of the proinflammation mediators S100a8/a9 (11). Prolonged ZD (23 weeks) 
leads to an expanded cancer-associated inflammatory program (10) and induction of an oncogenic 
miRNA signature with miR-31 as the top upregulated species (12), as also observed in human 
ESCCs (13, 14). 
 miR-31 is among the most frequently dysregulated microRNAs in human cancers (15). 
Depending on tumor type, miR-31 can be up- or downregulated, thus exhibiting oncogenic or 
tumor suppressive roles in cancers. Notably, miR-31 is overexpressed and oncogenic in colorectal 
cancer (16), lung cancer (17), and squamous cell carcinomas (SCCs), including ESCC (13, 14), 
tongue SCC (18), head and neck SCC (19), and skin SCC (20), but it is downregulated in serous 
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ovarian cancer (21). , The mechanisms by which miR-31 upregulation contributes to ESCC 
initiation and progression are not understood. In the present study, the biological functions of miR-
31 in esophageal neoplasia and the mechanism whereby Zn regulates miR-31 expression to 
promote ESCC were examined. 
 
Methods 
Animals Studies 
Animal protocols were approved by the Thomas Jefferson University Animal Care and Use 
Committee. Weanling male Sprague-Dawley rats were from Taconic Laboratory. Custom-
formulated ZD and ZS diets (Harlan Teklad, Madison, WI) were identical except for the amount 
of zinc, which was 3-4 ppm for ZD and 60 ppm for ZS diet.  Further details on animal studies, 
tissue isolation; RNA preparation; RT-QPCR; TaqMan miRNA assay; enzyme-linked 
immunosorbent assay; western blot, northern blot, caspase, luciferase, cell proliferation, and 
electrophoretic mobility shift assays; in situ hybridization (ISH); immunohistochemistry; and 
serum Zn measurement are in Supplementary Methods, available online. 
 
Locked-Nucleic Acid (LNA)-Modified Oligonucleotides 
Custom unlabeled and phosphothioated LNATM anti-rno-miR-31 oligonucleotide (5’-
CAGCTATGCCAGCATCTTGCCT-3’, complementary to nucleotides 1-22 in the mature miR-31 
sequence) and control rno-miR-31 scrambled oligonucleotide (5’-
GTGTAACACGTCTATACGCCCA-3’) were obtained from Exiqon (Vedbaek, Denmark). 
  
Human ESCC Samples and Cell Lines 
Twelve cases of formalin-fixed paraffin-embedded (FFPE) human ESCC samples were 
obtained from Thomas Jefferson University Hospital, Philadelphia, PA, USA. Human ESCC cell 
lines (KYSE-series) that were established from primary ESCC tumors (22) were purchased from 
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German Collection of Microorganisms and Cell Cultures. Human esophagus Het-1A was from 
American Type Culture Collection (ATCC). The cells were cultured in RPMI 1640 (Life 
Technologies) with 5% fetal bovine serum at 37oC with 5% CO2. 
 
miRNA and mRNA Expression Profiling and Analyses 
The Ohio State University custom miRNA microarray chips (OSU_CCC version 3.0) and 
Affymetrix Rat Genome 230 2.0 GeneChip (Affymetrix), respectively. See Supplementary 
Methods for details. The ArrayExpress accession numbers for miRNA and mRNA expression 
profiling are E-MTAB-2208 and E-MTAB-2315, respectively 
 
ChIP-sequencing 
The ChIP reaction was performed at Active Motif (Carlsbad, CA), as detailed in Supplementary 
Methods. Briefly, an aliquot of esophageal chromatin (30 μg) was precleared with protein A 
agarose beads (Invitrogen). DNA was immune-precipitated with anti-H3K4me1 (Active Motif, 
39297, Lot.1), anti-H3K4me3 (Active Motif, 39159 Lot.4), or anti-H3K27me3 (Millipore 07-449, 
Lot. JBC1854858). ChIP sequencing at 50 bp single end (approximately 40M reads/sample) 
was performed on Illumina HiSeq 2000 at HudsonAlpha Genomic Service Laboratory 
(Huntsville, Alabama). 
 
Peak Calling and Data Analysis 
Details are given in Supplementary Methods. Briefly, the collection of aligned reads were filtered 
to remove artifacts and mapped to the rat genome (rn4) using the Bowtie (23) algorithm. The 
number of uniquely mapped monoclonal reads for each ChIP-seq group is shown in 
Supplementary Table 4. To identify enriched regions of histone modifications ChIP-seq data, 
peak calling was performed using 0 algorithm (24).  
MOTIF-Finding and Quality Control 
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To find TFBs, we used rat genome (rn4) and Jaspar (25) and TRANSFAC database (26). 
Further details are given in Supplementary Methods. 
 
Statistical Analysis 
Values are expressed as mean ± standard deviation. The Student t-test was used to detect 
differences in comparisons involving only 2 groups. Data between the 4 subject groups were 
analyzed by analysis of variance.  For some variables (caspase, NF-kB p65 and miR-31 levels), 
a logarithmic transformation was performed to minimize the effects of heteroscedasticity. 
Differences among the groups were assessed using the Tukey-HSD post hoc t-test for multiple 
comparisons. Statistical tests were two-sided and were considered significant at P< .05. 
Statistical analysis was performed using R (http://www.R-project.org). 
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Results 
Establishment of a Rat Esophageal Neoplasia Model Overexpressing miR-31 
Previously (12) we examined the effect of long-term ZD (23 weeks) on miRNA expression in eight 
rat tissues by nanoString miRNA profiling assay, and miR-31 overexpression was documented in  
esophagus and two other stratified squamous epithelial tissues (tongue and skin) and in peripheral 
blood mononuclear cells. To establish an in vivo esophageal neoplasia model overexpressing miR-
31 for examining conditions that lead to human ESCC initiation, we determined if short-term ZD (5-
weeks) that produces a hyperplastic esophageal phenotype with a proinflammation gene signature 
(11) induces miR-31 upregulation as does long-term ZD (12). For this, we performed an array-
based miRNA expression profiling (27) of esophageal mucosa from weanling rats fed ZD or Zn-
sufficient (ZS) diet for 5 weeks (n=4/dietary group).  Fourteen dysregulated miRNAs were identified 
in ZD esophagus (q-value <10% [q-value is the minimum false discovery rate (FDR) at which the 
test may be called significant], Supplementary Table 1). Notably, miR-31 was the most upregulated 
species (ZD vs ZS = 10-fold upregulation, q value=0%).  This finding was verified by quantitative 
PCR (qPCR) (Figure 1A) and northern analyses (Figure 1B), using RNA samples from ZD and ZS 
esophagus (n=8 rats per group). Using the same RNA assessment methods, we found that 5 
weeks after ZD rats were switched to a ZS diet, the ZD-induced miR-31 overexpression was 
returned to normal ZS level (ZR/5wk rats; Figure 1, A and B). Thus, miR-31 expression is 
responsive to Zn treatment, establishing a short-term ZD esophageal preneoplasia model for study 
of effects of miR-31 overexpression and silencing.  
 
In Vivo Anti-miR-31 Delivery in Zn-Deficient Rat Esophageal Preneoplasia Model 
LNA-modified oligonucleotides are a class of RNA that exhibits in vivo high biostability, low toxicity, 
and adequate biodistribution (28). LNA-anti-miR-122 oligos were shown to mediate effective in vivo 
inhibition of liver-expressed miR-122 function in rodents (29) and nonhuman primates (30).  In a 
phase 2a clinical trial to treat patients with hepatitis C virus (HCV) infection, miravirsen (an LNA-
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modified inhibitor of miR-122) showed dose-dependent reductions in HCV RNA levels, thus 
demonstrating a therapeutic effect by targeting a host miRNA (31). 
 To inhibit esophageal miR-31 expression in vivo in Zn-deficient rats, we used LNA-anti-miR-31 
oligonucleotide (complementary to nt 1-22 in the mature miR-31 sequence, hereafter called anti-
miR). As depicted in Figure 1C, male weanling rats received a ZD or ZS diet and were randomized 
into 4 groups: ZD/anti-miR, ZD/LNA-scrambled, ZD/saline, and ZS/saline. The animals received 10 
doses of anti-miR, scrambled oligos, or saline, over a period of 5-weeks. During the 5-week study, 
the growth rate of all ZD groups was comparable to pair-fed ZS rats (Figure 1E). Regardless of 
treatment, serum Zn level in the three ZD groups was similar (~50 μg/100 ml), but lower than in ZS 
rats (P < .001, Figure 1D).  
 After 5 weeks of ZD diet, qPCR analysis (Figure 1F) showed that ZD controls had markedly 
higher miR-31 levels in esophagus, tongue, and circulating blood (P = .009 to < .001) than the ZS 
counterpart, a result consistent with long-term ZD (23 weeks) (12). Importantly, anti-miR-31 
treatment resulted in ~60% inhibition of miR-31 expression in the three tissues vs counterpart ZD 
controls (Figure 1F. Esophagus: ZD/anti-miR vs ZD/scrambled, P = .002. Tongue: ZD/anti-miR vs 
ZD/scrambled, P < .001.  Blood: ZD/anti-miR vs ZD/scrambled P < .001). The qPCR findings were 
confirmed at the cellular level by in situ detection of miR-31 in FFPE esophageal/lingual tissues. As 
shown in Figure 1G (esophagus) and Figure 2A (tongue), anti-miR-31 treatment resulted in an 
overall reduction in the scope and intensity of miR-31 signal in ZD/antimiR esophageal/lingual 
epithelia vs ZD controls (n=10 rats/cohort). Thus, despite continued dietary Zn-deficiency, anti-
miR-31 delivery effectively inhibited ZD-induced miR-31 expression in the esophagus/tongue. 
 Macroscopically, anti-miR treated ZD esophageal epithelia were strikingly less swollen than 
control ZD esophagi. Histologically, the ZD/anti-miR cohort showed a markedly thinned epithelium 
with fewer cell layers than the hyperplastic ZD/scrambled cohort (Figure 3A). These findings 
demonstrate that miR-31 inhibition prevented the development of a hyperplastic esophageal 
phenotype in rats in spite of their ZD diet.  
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 In addition to the esophagus, anti-miR-31 treatment prevented the development of a ZD-
induced hyperplastic tongue epithelium (32), as evidenced by a thinned epithelium (Figure 2B). 
Moreover, throughout the 5-week study period, anti-miR-treated ZD rats showed a near normal 
hair coat while ZD/saline or ZD/scrambled rats typically developed a poor coat with alopecia. 
Because ZD induces miR-31 expression in squamous skin associated with an inflammatory 
phenotype (12), it is likely that the improved skin phenotype in ZD rats was due to inhibition of miR-
31 by anti-miR in skin, as in esophagus, tongue, and blood (Figure 1F).  
 
miR-31 Antagonism  and Esophageal Cellular Proliferation and Apoptosis 
To assess esophageal cellular proliferation, we employed the proliferative marker PCNA. 
Immunohistochemical (IHC) analysis showed that the cell proliferation index (% of intensely 
stained PCNA-positive nuclei, expressed as mean ± standard deviation, n=10 samples/group) in 
the ZD/anti-miR esophagus (27±5.1%) was markedly reduced (P < .001) relative to control 
ZD/saline (48±7.3%) or ZD/scrambled esophagus (47±4.2%) (Figure 3B). Similarly, immunoblot 
analysis showed reduced PCNA expression in ZD/anti-miR esophagi (Figure 3C) as well as in 
ZD/anti-miR tongue (Figure 2C) relative to ZD controls. Thus, miR-31 inhibition led to prominently 
decreased cellular proliferation.  
 To assess apoptosis induction, a luciferase-based chemical assay was used. ZD/anti-miR 
esophagus showed statistically significantly higher caspase 3/7 (P = .005, fold change = 10.7) and 
caspase 9 activities (P = .019, fold change = 3.8) than ZD/saline esophagus (Figure 3D), indicating 
that miR-31 inhibition induced apoptosis. Together, the data indicate that miR-31 inhibition 
suppresses the hyperplastic ZD esophageal phenotype via reduction of cell proliferation and 
activation of apoptosis. 
 
Identification of Physiological miR-31 Targets in Esophageal Neoplasia 
To identify genes with altered transcript levels in response to miR-31 silencing in vivo, we 
performed genome-wide expression profiling of esophageal mucosa from the 4 animal groups at 
 11 
48 h after the final LNA-antimiR dose (Supplementary Table 2), using Affymetrix Rat Genome 230 
2.0 GeneChip (n=5 rats/treatment group). Hierarchical clustering of mRNA profiles revealed that 
the expression pattern in ZD/anti-miR esophagus was different from the control ZD/scrambled and 
ZD/saline esophagus, which were similar but distinct from ZS/saline esophagus (Figure 3E), 
implying that a large pool of the upregulated mRNAs in ZD/anti-miR RNAs correspond to 
derepressed miR-31 targets (29). Analysis of the array data revealed that the list of derepressed 
genes in ZD/anti-miR vs ZD/saline esophagus and in ZD/anti-miR vs ZD/scrambled esophagus 
were similar. In addition, the list of differentially expressed genes were similar in ZD/scrambled vs 
ZS/saline and in ZD/saline vs ZS/saline, indicating that LNA/scrambled had little effect on gene 
expression. Guided by miR-31 target prediction bioinformatics, 13 derepressed genes (Figure 3F) 
were chosen from the intersection analysis between a joint set of genes from ZD vs ZS rats and 
that from ZD vs ZD/anti-miR group. To validate this prediction, qPCR analysis was 
performed (Figure 3G).  Of the 10 genes that showed derepression with anti-miR 
treatment, six genes, including Stk40 (P < .001), Cpm (P = .02), Acta2 (P = .02), Ces1d (P = .004), 
Ly6e (P = .01), and Sft2d2 (P = .03) achieved a statistically significant difference between ZD/anti-
miR and ZD controls (Figure 3G), thereby validating the bioinformatics prediction (Figure 3F) that 
such genes would be derepressed after miR-31 silencing.   
Stk40 (33, 34) and Cpm (35) are of particular interest because of their roles in inflammation. 
We then determined if miR-31 directly interacts with Stk40 3’UTR by cotransfecting a pGL3 3¢ UTR 
luciferase reporter vector with synthetic miR-31 (Figure 4, A-C). A two-fold decrease in luciferase 
activity was observed, indicating a direct interaction between the miRNA and Stk40 3¢ UTR. Target 
gene repression was rescued by deletions in the complementary seed sites (fold change = 1.7, 
Figure 4C). These data establish that Stk40, a known negative regulator of NF-kB mediated 
transcription (33), is a miR-31 direct target. The regulation of Stk40 by miR-31 has been reported 
in ovarian cancer cells (21) and primary keratinocytes in psoriasis (34). Additionally, we 
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demonstrated that the Cpm 3’ UTR is a miR-31 direct target by using the 3¢ UTR luciferase 
reporter assay (Figure 5A). We showed by western blot that CPM protein was downregulated in 
hyperplastic ZD esophagus that overexpresses miR-31, and was restored upon miR-31 inhibition 
(Figure 5B).  Although CPM has emerged as a potential cancer biomarker (35), the mechanism by 
which CPM contributes to carcinogenesis remains to be determined.  
 
Anti-miR-31 Effects on STK40-NF-kB Based Inflammatory Pathway  
We next focused our study on Stk40 because of its role in regulation of NF-kB (33), a key mediator 
of inflammation (36). The ZD-induced esophageal preneoplasia is accompanied by cytoplasmic 
NF-kB p65 overexpression and nuclear translocation of NF-kB phospho-p65 (37). We showed by 
enzyme-linked immunosorbent assay (ELISA) that miR-31 inhibition led to statistically significantly 
lower NF-kB p65 levels in ZD/anti-miR esophageal lysates as compared with control ZD lysates (P 
= .002, fold change = -2.8, Figure 4E), a result confirming that miR-31 inhibition suppresses NF-kB 
activity (34).  To determine whether a connection occurs among miR-31, STK40, and downstream 
NF-kB signaling in esophageal neoplasia, we performed in situ detection of miR-31 expression 
combined with IHC analysis of the NF-kB p65-RAGE-S100A9 pathway (11), using FFPE 
esophageal tissues. In hyperplastic ZD/scrambled esophagus (Figure 4F), miR-31 overexpression 
was associated with downregulation of STK40 protein and accompanying upregulation of the NF-
kB p65-RAGE-S100A9 inflammatory pathway. Remarkably, in vivo anti-miR-31 delivery reduced 
miR-31 expression, upregulated STK40 protein expression, and abolished this NF-kB p65-RAGE 
inflammation network, resulting in a non-inflammatory esophageal phenotype that resembles the 
Zn-sufficient esophagus (Figure 4F).  These in vivo findings show for the first time the important 
connections between oncomiR-31, STK40, and NF-kB p65-controlled signaling in esophageal 
neoplasia. 
Cellular Localization of miR-31 Expression in Human ESCC Tissue 
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The cellular origins of miRNAs are of importance in the understanding of the mechanistic roles 
of miRNAs in tumor development. In order to determine the cellular localization of miR-31 in 
human ESCC, we evaluated miR-31 expression in archived FFPE human ESCC tissues by ISH 
(n=12 cases). Consistent with our previous study on miR-31 ISH in ESCC from carcinogen-
treated ZD rats (12), all 12 cases of human ESCCs showed an intense and abundant miR-31 
ISH signal in the tumor tissues and a moderate miR-31 signal in the adjacent esophageal 
mucosa (Figure 6). These results represent the first in situ detection of miR-31 in human ESCC, 
thereby providing support for miR-31 as a potential prognostic and/or therapeutic marker for 
ESCC.  
 
Overexpression of miR-31 and STK40 and NF-kB Expression in Human ESCC Cells  
To define the role of STK40 in human ESCC cells, we analyzed cell proliferation and apoptosis 
after STK40 silencing. STK40 silencing, as shown by western blot, decreased caspase 3/7 activity 
(P = .015) and increased viability of esophageal cancer cells (P = .03) (Figure 4D). These results 
are consistent with the cell proliferation (Figure 3B) and apoptosis (Figure 3D) data in ZD rat 
esophagus that documented miR-31 overexpression with accompanying STK40 downregulation 
(Figure 4F). Next the expression of miR-31, STK40, RELA, and NF-kB1 were analyzed by qPCR in 
six human ESCC cell lines of the KYSE-series (22) (KYSE-450, -410, -520, -510, -180, -270) 
(Figure 4G). miR-31 was overexpressed in all six ESCC cell lines vs human normal esophagus cell 
line HET-1A. In four cell lines (KYSE-450, -410, -520, and -510), miR-31 overexpression was 
accompanied by low STK40 expression and an inverse relationship between STK40 and 
RELA/NF-kB1. These data document, for the first time, the important connections among 
oncomiR-31, STK40, and NF-kB in human ESCC cells.  
 
Activation of miR-31 Promoter Region in Zn-Deficient Esophagus 
Finally, to elucidate the mechanisms by which miR-31 is upregulated by Zn-deficiency, we 
performed chromatin immunoprecipitation followed by high-throughput sequencing (ChIP-seq) on 
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esophagi from Zn-modulated rats (ZD, ZR, ZS). This analysis used antibodies for chromatin 
modification marks H3 lysine 4 trimethylation (H3K4me3), H3 lysine 4 monomethylation 
(H3K4me1), and H3 lysine 27 trimethylation (H3K27me3). Enrichment of H3K4me3 binding signals 
indicates the presence of a promoter region, whereas those of H3K4me1 and H3K27me3 
represent marks for enhancers and repressed regions, respectively (38)   
 To identify enriched regions of histone modifications in ChIP-seq data, we performed peak-
calling analysis using SICER algorithm (24) (Supplementary Methods). By analyzing the genome 
occupancy of H3K4me3, we identified a promoter region ~30 kb (kilobases) upstream of the 
mature sequence location of miR-31 (Figure 7A). We used Integrative Genomics Viewer (IGV) (39) 
to visualize the promoter region of miR-31. H3K4me3 binding signals were statistically significantly 
enriched in ZD vs ZS esophagus (P < .001, Figure 7B), indicating that the promoter is activated in 
ZD esophagus. With Zn-replenishment, H3K4me3 levels were significantly reduced (ZD vs ZS = 
2.58 as compared to ZR vs ZS=1.52, Figure 7B), accompanied by a near normal miR-31 level 
(northern blot, Figure 1B and ISH, Figure 7C) and esophageal phenotype (Figure 7C). On the 
other hand, the histone mark for enhancer H3K4me1 binding signals were minimally enriched in 
ZD esophagus and no enriched locations were found for repressor H3K27m3 binding signals 
(Supplementary Figure 2; Supplementary Table 3).  
This miR-31 promoter region is conserved in humans and rats (Supplementary Figure 1). To 
test the presence of putative cis-regulatory elements (promoters, enhancers) in human, we used 
public ChIP-seq data of several human cell lines and identified binding sites of PolII in the CpG 
island corresponding to rat island 77. Using chromatin state dynamics from ENCODE chromatic 
portal (40), we determined that this region is characterized by the presence of poised or active 
promoters (Supplementary Figure 1A). Because a genome map of cis-regulatory elements is not 
available in rat genome, we used Blat, the University of California, Santa Cruz (UCSC) Genome 
Browser (41) to find a conserved region in rats similar to CpG island 77. Using Blat 
(Supplementary Methods), we found a region with 85.2% similarity with humans. This region is 
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indeed the promoter region that we have identified in rats (ChIP-seq data, Supplementary Figure 
1B). 
  
Identification of RelA and Sp1 in miR-31 Promoter Region 
We downloaded the DNA sequence from the rat genome (rn4) located at chr5: 108.520.153-
108.537.803 that showed the highest continuous peak enriched in ZD esophagus for chromatin 
mark H3K4me3. To find the Transcription Factor Binding Site (TFBs), we used Jaspar Core (25) 
and TRANSFAC database (26) and identified one predicted RelA (p65 subunit of NF-kB) binding 
site: GGGAATTCCCC (5:108,526,856-108,526,866 [+]) and one TFBs for Sp1: 
GGACGCCCCGCCCCGGCCCCGCCCCGACGG (5:108,527,171-108,527,194 [+]). These 
sequences are both located within the miR-31 promoter region (Figure 7A). The TFBs for rat NF-
kB p65 (subunit of NF-kB transcription factor complex) is located 2 kb downstream of the CpG 
island 94 (Figure 7A).  We cloned this sequence of ~400 bp in a promoterless vector (PGL3basic) 
and cotransfected this construct along with a NF-kB p65 siRNA or a dominant active (DA) I-kBa in 
293T cells. NF-kB p65 knockdown or inhibition resulted in a greater than two-fold decrease in miR-
31 promoter activity, suggesting that this microRNA is transcriptionally regulated by NF-kB p65 
(Figure 7D). Sp1 is located within the CpG island of the miR-31 promoter (Figure 7A) and was 
validated through electrophoretic mobility shift assay (Figure 7E). These findings indicate that the 
putative promoter region may be bound by NF-kB transcription factor complex together with the 
Sp1 transcription factor. 
 
Discussion 
ESCC is a lethal cancer due to diagnosis at advanced stage and lack of effective therapies. In 
comparison with other human cancers, ESCCs exhibit few expression changes in microRNAs and 
no bona fide physiological targets. miR-31 acts as an oncomiR in ESCC (13, 14) (Figure 6), and 
tongue SCC (18) (12). Its biological functions in these cancers, however, have not been defined 
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and its potential as a therapeutic target not assessed. Our rat model that recapitulates features of 
human ESCC, including Zn-deficiency, miR-31 overexpression, and inflammation (8, 13, 14, 42) 
provides an opportunity to decipher the mechanism of oncomiR-31 function in ESCC and its 
relationship to ESCC promotion by dietary Zn deficiency. Using this model, the current study 
shows that in vivo miR-31 antagonism by systemically administered LNA-anti-miR decreased miR-
31 overexpression in esophagus/tongue and circulating blood and prevented the development of a 
preneoplastic phenotype in esophagus and tongue in ZD rats. Importantly, we show that systemic 
delivery of anti-miR-31 reduces cellular proliferation, activates apoptosis, and represses the miR-
31 associated STK40-NF-kB based inflammation signaling in the esophagus. Thereby, the 
tumorigenic effects of Zn-deficiency are overcome and esophageal neoplasia inhibited. These data 
are the first evidence that in vivo anti-miR-31 delivery exerts multiple anticancer activities and 
inhibits ESCC neoplasia. 
 To pinpoint biologically significant miR-31 targets from the hundreds of putative targets 
generated by target prediction algorithms (43), our approach has led to identification of Stk40 as a 
biological miR-31 target by using in vivo miR-31 antagonism and microarray analysis of 
derepressed genes. Although Stk40 was identified as a miR-31 direct target in ovarian cancer cell 
lines (21) and psoriasis (34) and Stk40 is a known negative regulator of NF-kB signaling, the 
important connections between miR-31, Stk40, and NF-kB signaling has not been demonstrated in 
human cancers. Our study shows for the first time that systemic delivery of anti-miR-31 
suppresses the esophageal neoplasia by derepressing its target, Stk40, and inhibiting the 
associated STK40-NF-kB controlled inflammatory pathway. Because the same connections among 
miR-31, Stk40, and NF-kB signaling is also shown in human ESCC cell lines, our in vivo results 
provide a mechanistic rationale for clinical development of miR-31 as a biomarker and treatment 
target for ESCC patients. 
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 Transcription factors are known to regulate miRNA expression in a tissue- and disease-specific 
manner (44). By performing ChIP-seq on esophagi from Zn-modulated rats using an antibody for 
chromatin modification mark, H3K4me3 that detects promoters (45), our analysis identified a miR-
31 promoter region activated in ZD esophagus. Dietary Zn-replenishment restored the regulation of 
this genomic region to the inactive state, miR-31 levels, and the hyperplastic esophageal 
phenotype to near normal. These data provide the first evidence that miR-31 promoter activity is 
regulated by dietary Zn.  In addition, our motif-finding analysis demonstrates the presence of an 
NF-kB binding site in the miR-31 promoter region. NF-kB p65 knockdown resulted in a decrease in 
miR-31 promoter activity, indicative of transcriptional regulation of miR-31 by NF-kB p65. 
Together, these data define a mechanism whereby Zn-deficiency upregulates miR-31 by activating 
its promoter/TFBs and unleashing miR-31-associated STK40-NF-kB controlled inflammatory 
signaling to produce a preneoplastic phenotype.  
 A limitation of this study is the fact that the endpoint was the early hyperplastic and 
inflammatory esophageal phenotype rather than esophageal cancer itself. Studies are in progress 
to specifically address this issue. 
In summary, our in vivo work defines the signal pathway underlying the interaction of Zn-
deficiency and miR-31 overexpression in promoting esophageal neoplasia (Figure 8). OncomiR-31 
is a critical target involved in ESCC pathogenesis. Antagonism of miR-31 leads to suppression of 
esophageal neoplasia, thereby providing support for clinical development of miR-31 as a 
biomarker and therapeutic target for this deadly disease.  
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Figure Legends 
Figure 1. Systemic delivery of locked-nucleic-acid mediated anti-miR-31 in Zn-deficient (ZD) rat 
esophageal preneoplasia model. A) qPCR analysis of esophageal miR-31 expression in Zn-
modulated rats, using rat snoRNA as the normalizer (n = 8 rats/group, ‡P < .001, Tukey-HSD post 
hoc unpaired t-test for multiple comparisons. Error bars represent standard deviation). B) Northern 
analysis of esophageal miR-31 expression in Zn-modulated rats (n = 5-8 rats/group). C-G) 
Systemic delivery of anti-miR-31 to ZD rats. C) Study design. D) Serum Zn levels are similar 
among ZD groups but statistically significantly lower than Zn-sufficient (ZS) rats (n = 12-20/group, 
‡P < .001. Error bars represent standard deviation). E) Growth curves are similar in all 4 animal 
groups. Error bars represent standard deviation. F) qPCR analysis of miR-31 expression in 
esophagus, tongue, and blood in 4 animal groups, using rat snoRNA as the normalizer (n = 12-20 
rats/group. Esophagus: ZD/saline vs ZS/saline (‡P < .001), ZD/scrambled vs ZS/saline (‡P < .001), 
ZD/anti-miR vs ZD/saline (†P = .004), and ZD/anti-miR vs ZD/scrambled (†P = .002). Tongue: 
ZD/saline vs ZS/saline (†P = .002), ZD/scrambled vs ZS/saline (†P = .001), ZD/anti-miR vs 
ZD/saline (‡P < .001) and ZD/anti-miR vs ZD/scrambled (‡P < .001). Blood: ZD/saline vs ZS/saline 
(†P = .009), ZD/anti-miR vs ZD/saline (‡P < .001) and ZD/anti-miR vs ZD/scrambled (‡P < .001). 
Error bars represent standard deviation). G) In situ hybridization (ISH) analysis shows 
moderate/infrequent miR-31 signal (blue, 4-nitro-blue tetrazolium and 5-brom-4-chloro-3′-
indolylphosphate); counterstained by nuclear fast red) in ZD/anti-miR and ZS/saline esophagus, 
but strong/abundant miR-31 signal in hyperplastic ZD controls. No ISH signal was seen with mm-
miR-31 (two mismatches). Scale bars: left, 100 μm; right, 25 μm.  Open rectangles are insets 
shown in panels to the right.  All statistical tests were two-sided. 
Figure 2. Anti-miR-31 effects on Zn-deficient (ZD) rat lingual preneoplasia. A) In situ hybridization 
(ISH) analysis of miR-31 expression. miR-31 signal (blue, 4-nitro-blue tetrazolium and 5-brom-4-
chloro-3′-indolylphosphate) is moderate/infrequent in ZD/anti-miR tongue but strong/abundant in 
hyperplastic ZD controls. Scale bars: left, 100 μm; right, 25 μm.  Open rectangles are insets shown 
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in panels to the right. B) Hematoxylin and eosin (H&E) staining showing a thinned ZD/anti-miR 
lingual epithelium vs hyperplastic ZD control tongue; immunohistochemical showing few PCNA-
positive nuclei (red, 3-amino-9-ethylcarbazole substrate-chromogen,) in thinned ZD/anti-miR 
tongue vs abundant PCNA-positive nuclei in proliferative ZD/scrambled control (H&E, Scale bar, 
100 μm. PCNA, Scale bar, 100 μm; left 25 μm).  Open rectangles are insets shown in panels to the 
right. C) Immunoblot analysis shows reduced PCNA expression in tongue following systemic 
delivery of anti-miR-31. 
Figure 3. Anti-miR-31 effects on Zn-deficient (ZD) rat esophageal preneoplasia and potential miR-
31 targets. A) Histology of ZD/anti-miR vs ZD/scrambled esophagus (hematoxylin and eosin-stain, 
Scale bar, 100 μm). B) Immunohistochemical analysis shows few PCNA-positive nuclei (red, 3-
amino-9-ethylcarbazole substrate-chromogen) in thinned ZD/anti-miR esophagus vs abundant 
PCNA-positive nuclei in proliferative ZD controls (Scale bars: left, 100 μm; right, 25 μm). Open 
rectangles are insets shown in panels to the right.   C) Immunoblot analysis shows reduced PCNA 
expression in esophagus following systemic delivery of anti-miR-31. D) Luminescent assays show 
caspase 3/7 and caspase 9 activities in the 4 animal groups (RLU=relative light units, n = 5-8 
rats/group. Caspase 3/7, †P = .005. Caspase 9, *P = .019, Tukey-HSD post hoc t-test. Error bars 
represent standard deviation). E) Unsupervised hierarchical cluster of the most significant genes 
(upregulated genes, red; downregulated genes, green) in rat esophagi from the 4 animal groups 
(Figure 1C). F) Barplot graph showing expression of 13 predicted miR-31 targets in ZD esophagus 
that were derepressed after anti-miR treatment. G) qPCR analysis of the predicted genes, using 
OAZ1 as normalizer (n = 8-12 rats/ group. Error bars represent standard deviation. Tukey’s 
multiple comparison test. Stk40: ZD/anti-miR vs ZD/saline, ZD/anti-miR vs ZD/scramble, ‡P < .001.  
Cpm: ZD/anti-miR vs ZD/saline, ZD/anti-miR vs ZD/scramble, *P = .02. Acta2: ZD/anti-miR vs 
ZD/saline, *P = .02; Ces1d, ZD/anti-miR vs ZD/saline, †P = .004; Ly6e: ZD/anti-miR vs ZD/saline, 
*P = .01; Sft2d2: ZD/anti-miR vs ZD/saline, *P = .03). All statistical tests were two-sided. 
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Figure 4. Anti-miR-31 effects on Stk40 – NF-kB based inflammatory signaling. A-C) Stk40 3’ UTR 
is a miR-31 direct target. A) Stk40 3’UTR presents two miR-31 binding sites. B) Alignment of miR-
31 seed region with Stk40 3’UTR. Sites of target mutagenesis are indicated (- = deleted 
nucleotides). C) Luciferase reporter assays indicates direct interactions between miR-31 and 
Stk40. Error bars represent standard deviation. ‡P < .001. D). STK40 silencing affects proliferation 
and apoptosis of esophageal squamous carcinoma (ESCC) cells. Western blot showing STK40 
downregulation in KYSE-70 ESCC cells after transfection with STK40 siRNA; cell proliferation 
assay showing increased cell survival (*P = .03, error bars represent standard deviation) and 
luminescent assays showing decreased caspase 3/7 activity after STK40 silencing (*P = .015, 
error bars represent standard deviation). E) Enzyme-linked immunosorbent assay shows NF-kB 
p65 expression was statistically significantly reduced in Zn-deficient (ZD)/anti-miR vs control ZD 
cohorts (n=6-8 rats/group, Tukey-HSD post hoc unpaired t-test, †P = .002. Error bars represent 
standard deviation). F) In situ hybridization (ISH) analysis of miR-31 expression; 
immunohistochemical analysis of STK40, NF-kB p65, RAGE, S100A8, and S100A9 expression in 
esophageal formalin-fixed paraffin-embedded sections. ZD/anti-miR (middle) and ZS (right) 
esophagi showing weak/diffuse miR-31 ISH signal (blue, 4-nitro-blue tetrazolium and 5-brom-4-
chloro-3′-indolylphosphate); strong cytoplasmic STK40 (brown, 3,3′-diaminobenzidine 
tetrahydrochloride [DAB]) but weak cytoplasmic NF-kB p65, RAGE (brown, DAB), and S100A8/A9 
(red, 3-amino-9-ethylcarbazole substrate-chromogen) immunostaining. In contrast, hyperplastic 
ZD/scrambled esophagus (left) showing strong/abundant miR-31 ISH signal, weak/diffuse 
cytoplasmic STK40 immunostaining, but strong cytoplasmic immunostaining of NF-kB p65, RAGE, 
and S100A8/A9 protein. (Scale bar, 25 μm). G) qPCR analysis of miR-31, STK40, RELA, and NF-
kB1 expression in 6 human esophageal squamous cell carcinoma (ESCC) cell lines and control 
esophageal squamous epithelial cells HET-1A, using RNU44 and OAZ1 and as normalizer for 
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miR-31 and mRNA, respectively. qPCR analysis was performed in triplicate. All statistical tests 
were two-sided. 
 
Figure 5. Cpm as a miR-31 direct target.  A) Luciferase report assay showing direct interaction 
between miR-31 and Cpm. Inactivation of miR-31 binding site by site-direct mutagenesis rescues 
luciferase activity (experiments were performed three times. ‡P < .001, error bars, ± standard 
deviation). All statistical tests were two-sided.  B) Western blot showing increase in CPM protein 
expression in Zn-deficient (ZD)/antimiR esophageal lysates relative to control ZD samples. 
 
Figure 6. Localization of miR-31 in human esophageal squamous cell carcinoma (ESCC) tissue by 
in situ hybridization (ISH). Representative sections of ESCC tissues are shown (hematoxylin & 
eosin [H&E]-stain). miR-31 ISH signal (blue, 4-nitro-blue tetrazolium and 5-brom-4-chloro-3′-
indolylphosphate; counterstain, nuclear fast red) was intense and abundant in near serial formalin-
fixed paraffin-embedded sections of ESCC tumor tissue but moderate in adjacent non-tumorus 
esophageal mucosa (Case 2). No ISH signal was obtained with mismatched mm-miR-31 (2 
mismatches). Open rectangles are insets illustrated in panels directly below.  Scale bars: 100 µm 
(H&E, miR-31, and mm-miR-31); 25 µm (miR-31 inset).  
 
Figure 7.  ChIP-seq identification of the promoter region of miR-31 and TFBs. A) Integrative 
Genomics Viewer view shows the putative miR-31 promoter region in Zn-deficient (ZD) rat 
esophagus:  miR-31 (red arrow), CpG island (red box), and TFBs NF-kB/Sp1 (blue box). The 
values on the y-axis for ChIP-seq data are input normalized intensities; the values on red barplots 
are normalized read counts/library size x 1,000,000. B) Table shows differentially enriched regions 
(H3K4me3) among Zn-modulated groups (Zn-sufficient = ZS, Zn-replenished = ZR). C) 
Hematoxylin and eosin-stain analysis of histology, in situ hybridization analysis of miR-31 
expression, and immunohistochemical analysis of the proliferation marker PCNA of Zn-modulated 
esophagus (scale bars, 25 μm). D) NF-kB  transcriptionally activates miR-31. Luciferase 
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experiment shows downregulation of miR-31 promoter activity after NF-kB silencing (siRELA) or 
the overexpression of a NF-kB dominant active inhibitor (DAIKB) (experiments were performed 
three times. ‡P < .001, error bars, ± standard deviation). All statistical tests were two-sided. E) 
DNA mobility shift assay shows the binding of Sp1 to Sp1-probe motive. Lane 1: labeled Sp1-
motive probe. Lane 2: two complexes at different molecular weights (shift 1, shift 2) are formed by 
the addition of nuclear extracts from HELA cells to Sp1-motive probe. Lane 3: anti-Sp1 antibody 
disrupts the higher molecular weight complex (shift 2). 
Figure 8. Molecular pathway underlying interaction of Zn-deficiency and miR-31 overexpression in 
promoting esophageal preneoplasia. Zn-deficiency induces miR-31 overexpression leading to 
downregulation of its direct target Stk40. Stk40 downregulation activates NF-kB and Rage through 
S100a8/a9 dimer protein complex, thereby promoting inflammation and cellular proliferation to 
produce the preneoplastic esophageal phenotype. 
  
 
